⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VVOS News
Vivos Therapeutics, Inc. Common Stock
CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
accessnewswire.com
VVOS
Form 8-K
sec.gov
VVOS
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
globenewswire.com
VVOS
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
accessnewswire.com
VVOS
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
globenewswire.com
VVOS
Form 8-K
sec.gov
VVOS
Form 8-K
sec.gov
VVOS
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
globenewswire.com
VVOS
Form 8-K
sec.gov
VVOS
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
globenewswire.com
VVOS